SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending due to speculation surrounding its potential inclusion in the S&P 500, sparking bullish sentiment and driving conversations about the potential "index effect" and forced ETF buying. The community is actively discussing strategies around options and covered calls, while also weighing the potential for a "sell the news" reaction post-inclusion. Some are comparing Robinhood to other stocks that were added to the S&P 500.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as traders discuss the potential for inclusion in the S&P 500, though sentiment is mixed. The community debates whether it deserves inclusion as a bitcoin proxy, with some suggesting its fate is tied to bitcoin's price action, while others eye a potential sell-off if it's excluded. Discussions also involve covered call strategies and comparisons to other stocks added to the index.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around upcoming airdrops and staking opportunities. The coin's growing watcher count and bullish sentiment are fueling discussions about potential market cap milestones and ongoing buy contests. Community members express excitement about the project's long-term vision, developments and transparency.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is trending due to its impending addition to the S&P 500, driving forced ETF buying and increased liquidity, though some traders are anticipating a short-term pullback following the inclusion. Community discussions revolve around the potential for new all-time highs and the long-term implications of S&P 500 membership, with some skepticism regarding short reports from firms like Muddy Waters.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

Infinite Money Glitch ($IMG.X) is trending as the community rallies around its unique rewards system, which distributes Solana ($SOL.X) directly to holders, regardless of price fluctuations. Recent discussions highlight the strength and resilience of the community, with many emphasizing that holding $IMG.X provides passive income superior to traditional investments, while also mentioning a new partnership with Kimbo Slice Jr.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group Inc. is trending as the community debates the impact of its recent reverse stock split and a closed investment deal with Uber. While some investors express optimism about the company's technology and long-term potential, others are concerned about cash burn and dilution, contributing to a volatile stock price. Discussions also revolve around the company's management and future prospects within the competitive EV sector.

THE COQ FATHER BOSS

$BOSSCOQ.X is trending as the community discusses its potential and compares it to other meme coins. The coin is being mentioned alongside other crypto symbols, indicating interest in its growth within the meme coin sector. Community members are actively expressing their preference for $BOSSCOQ.X over similar coins.

Tidal Trust II - YieldMax MSTR Option Income Strategy ETF

YieldMax MSTR Option Income Strategy ETF

YieldMax MSTR Option Income Strategy ETF ($MSTY) is trending as investors discuss its recent performance, particularly in relation to MicroStrategy ($MSTR) and Bitcoin. Concerns are emerging regarding NAV erosion and the sustainability of dividend payouts, with some community members expressing bearish sentiment. Others remain optimistic, viewing dips as buying opportunities and emphasizing the potential for high yield and long-term gains, especially if $MSTR is included in the S&P 500.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue is trending due to reports linking Tylenol use during pregnancy to autism, sparking debate among investors and drawing attention to potential legal ramifications. While some dismiss the claims as overblown and see a buying opportunity, others express concern and anticipate further declines. Community discussions also involve the stock's dividend yield and potential recovery.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is trending as investors discuss the potential impact of warrant conversions, with some expressing frustration over the company's language regarding possible acquisitions. The community is also weighing oversold signals, awaiting news catalysts, and debating the stock's short-term direction amid broader discussions about solid-state battery technology and market manipulation. Some traders express bullish sentiment while others remain skeptical, citing past performance and management decisions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Compass Pathways Plc. (CMPS) slumped 47% on Monday afternoon after the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.compasspathways.com/News--Events-/news/news-details/2025/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-First-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx">results</a> from the late-stage trials of COMP360 in treatment-resistant depression fell short of market expectations.COMP360 is a synthetic, proprietary formulation of psilocybin. Psilocybin is part of a group of drugs called psychedelics or hallucinogens with the ability to alter one’s sense of perception.Compass Pathways said that a single dose of the drug reduced symptom severity by 3.6 points from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) as compared to placebo at week 6.The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.The company is also running another late-stage trial for the drug, which aims to evaluate the efficacy of two fixed doses taken three weeks apart.According to Compass Pathways, an estimated 21 million adults in the U.S. suffer from major depression, and approximately 9 million are drug-treated.Approximately a third of patients with major depressive disorder will develop treatment-resistant depression, which is defined as an inadequate response to two or more appropriate courses of approved medications.Following the announcement, Evercore ISI downgraded Compass Pathways to ‘In Line’ from ‘Outperform’ with a price target of $6, down from $11.The reduction in symptom severity by 3.6 points as compared to placebo on a standardized depression scale "underwhelmed," the analyst told investors, as per TheFly.This dataset does indicate Compass may have an approvable drug, but the firm noted that durability is a key component for commercial success, and this will remain a question with relatively unclear durability in a mid-stage trial and a weaker effect at 6 weeks in the late-stage trial.H.C. Wainright, however, is more optimistic and noted that the results from the late-stage study mark "a historic first for a psychedelic therapy." The data also positions COMP360 as "a potential first-in-class treatment in a large, underserved depression market," said the analyst, who reiterated a ‘Buy’ rating and $45 price target on the shares.On Stocktwits, retail sentiment around CMPS jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:631/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_23_at_12_27_47_PM_png_d7e1356560.webp" alt="CMPS's Sentiment Meter and Message Volume as of 12:25 p.m. ET on June 23, 2025 | Source: Stocktwits" width="631" height="60"><figcaption>CMPS's Sentiment Meter and Message Volume as of 12:25 p.m. ET on June 23, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that while the late-stage results were good, the market wants ‘groundbreaking’ results.<stembedurl>https://stocktwits.com/aaronmag13/message/618680560</stembedurl><a href="https://stocktwits.com/symbol/CMPS">CMPS stock</a> is down by about 35% this year and nearly 61% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/rezolve-ai-to-be-added-to-russell-indices-after-revenue-surge/chm57C7RRdR">Rezolve Ai To Be Added To Russell Indices After Revenue Surge: Retail Echoes Confidence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts

The company said it will discuss the “highly statistically significant and clinically meaningful” data with the U.S. Food and Drug Administration, which has yet to review it.

Equity

Nasdaq-listed shares of Autolus Therapeutics PLC (AUTL) were in the spotlight on Friday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-announces-positive-chmp-opinion">announced</a> that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) approve its Obe-cel therapy for the treatment of a particular type of blood cancer.Obe-cel is short for Obecabtagene Autoleucel. The CHMP has recommended that the European Commission approve it for the treatment of adult patients over the age of 26 with relapsed or refractory B-cell precursor acute Lymphoblastic Leukemia, an aggressive type of blood cancer that can also involve the lymph nodes, spleen, liver, central nervous system, and other organs.According to Autolus, there are about 6,000 new cases of acute Lymphoblastic Leukemia diagnosed every year in Europe.The committee’s recommendation was based on the results of the company’s open-label, multiple-centre study and will serve as the basis for the commission’s final decision on Autolus’ marketing authorization application.The European Commission's decision will apply to all 27 European Union Member States, Iceland, Norway, and Liechtenstein.Obe-cel received approval from the U.S. Food and Drug Administration in November 2024 and conditional marketing authorization from the U.K.’s Medicines and Healthcare Products Regulatory Agency in April.On Stocktwits, retail sentiment around AUTL improved from ‘bearish’ to ‘neutral’ territory over the past 24 hours while message volume remained at ‘neutral’ levels.<figure class="image"><img style="aspect-ratio:627/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_23_at_12_01_00_PM_png_a607fcc3b0.webp" alt="AUTL's Sentiment Meter and Message Volume as of 12:00 p.m. ET on May 23, 2025 | Source: Stocktwits" width="627" height="64"><figcaption>AUTL's Sentiment Meter and Message Volume as of 12:00 p.m. ET on May 23, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism about the therapy receiving approval in the EU.<stembedurl>https://stocktwits.com/Mancunian/message/615691105</stembedurl><a href="https://stocktwits.com/symbol/AUTL">AUTL stock</a> is down by about 42% this year and 61% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/amazon-backed-anthropic-claude-blackmails-engineer/ch0QVgWRbqH">Amazon-Backed Anthropic's AI Model Reportedly Blackmails Engineer Having An Affair To Avoid Being Shut Down In Test Run</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Autolus Therapeutics Gets Favorable Recommendation For Approval Of Cancer Therapy In EU: Retail Sentiment Brightens

CHMP has recommended that the European Commission approve the therapy for treating adult patients over the age of 26 with relapsed or refractory B-cell precursor acute Lymphoblastic Leukemia. 

Shares of biotech Galapagos NV (GLPG) dipped nearly 1% in pre-market trade on Tuesday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.glpg.com/press-releases/galapagos-announces-departure-of-thad-huston-cfo-and-coo-as-of-august-1-2025/">announced</a> the departure of its CFO and COO, Thad Huston, effective August 1, 2025.The company said Huston has decided to leave and return to the U.S. for personal and professional reasons. It added that it expects to announce a new CFO “in the coming months,” but did not share a definitive timeline.Huston joined Galapagos in July 2023 from Kite Pharma, Inc. Before that, he worked for over 25 years at Johnson &amp; Johnson.CEO Paul Stoffels said that Huston will stay in his role until Aug. 1 to “ensure a smooth handover of responsibilities.”Galapagos, which has operations in Europe and the U.S., reported its full-year 2024 financial results earlier this year. The company logged a 15% jump in total net revenue to €275.6 million (about $312 million), while diluted earnings per share fell to $1.12 from $3.21 year-over-year (YoY).As of the end of 2024, it had €3.3 billion in cash and financial investments and said that it intends to separate into two publicly traded companies and establish SpinCo with approximately €2.45 billion in current cash.A shareholder meeting regarding the separation of Galapagos into two publicly traded entities is expected to be convened in mid-2025.On Stocktwits, retail sentiment about Galapagos fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:650/148;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_15_at_8_24_57_AM_png_80bd7d6071.webp" alt="GLPG's Sentiment Meter and Message Volume as of 8:25 a.m. ET on April 14, 2025 | Source: Stocktwits" width="650" height="148"><figcaption>GLPG's Sentiment Meter and Message Volume as of 8:25 a.m. ET on April 14, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/GLPG">GLPG stock</a> is down by over 13% year-to-date and by nearly 19% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/johnson-and-johnsons-q1-earnings-beat-estimates/chQRaxWRbaH">Johnson &amp; Johnson’s Q1 Earnings Beat Estimates, 2025 Guidance Revised To Account For Intra-Cellular Therapies Acquisition: Retail’s Positive</a>For updates and corrections, email newsroom[at]stocktwits[dot]com(Exchange Rate: 1 Euro = 1.13 USD)

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Galapagos Announces CFO Exit With No Successor Named Yet: Retail’s Disappointed

The company expects to announce a new CFO “in the coming months.”

MoonLake Immunotherapeutics, a clinical-stage biotech firm valued at $2.6 billion, is generating excitement with its experimental treatment for hidradenitis suppurativa (HS), a chronic and painful skin condition.&nbsp;On Friday, Goldman Sachs upgraded the stock to a&nbsp;'Buy' from&nbsp;'Neutral,' with analyst Richard Law raising the price target from $62 to $82 — an 85% upside from current levels, CNBC&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2025/01/17/this-little-known-biotech-stock-is-a-buy-thats-primed-to-double-in-price-goldman-says.html">reported</a>.While MoonLake is gaining traction among institutional investors, it remains underfollowed on Stocktwits, with fewer than 600 watchers.&nbsp;Over the past year, retail interest has been budding, with a 12% increase in followers, even as the stock has fallen 26%.Law reportedly believes MoonLake's experimental nanobody treatment, sonelokimab (SLK), holds transformative potential.&nbsp;SLK demonstrated impressive efficacy in phase 2 trials, leading to optimism about its success in phase 3.&nbsp;Additionally, SLK's inclusion of AbbVie's Skyrizi — currently the standard of care for psoriatic arthritis (PsA) — as a reference treatment offers a key differentiator, according to the analyst.Law suggests that while this adds some risk, the potential to position SLK as superior in a competitive market far outweighs the drawbacks.Goldman Sachs isn't alone in its optimism. Oppenheimer included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena.&nbsp;The brokerage sees biotech equities as undervalued relative to other sectors, with strong catalysts like lower interest rates, robust M&amp;A prospects, and transformative data releases creating a favorable backdrop this year.MoonLake ended the third quarter (Q3) of 2024 with $493.9 million in cash, cash equivalents, and marketable securities, which the company said provides a runway through 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Over the past year, retail interest has been budding, with a 12% increase in followers, even as the stock has fallen 26%.

Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely?

Oppenheimer has included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena.

Current Price	$37.01
Prev Close	$36.15
Open	$36.41
Dividend Yield	N/A
50-Day Moving Average	$33.14
Beta	N/A
Avg. Volume	8,327.86
PE Ratio	N/A

52-Week High	$42.73
52-Week Low	$22.33
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

SBIO
ALPS Fund Services - ALPS Medical Breakthroughs ETF

Feed

News

Sentiment

Fundamentals

Info

Latest SBIO News

SBIO ALPS Fund Services - ALPS Medical Breakthroughs ETF